Fig. 6.

In vivo experiments corroborate PSMs as 5-LOX activators. a 5-LOX products in murine paws at different time points upon infection with S. aureus USA300. b 5-LOX products in murine paws 48 h post-infection with S. aureus and mutant strains (USA300, USA300∆psmαβ). 5-LOX products were analyzed by UPLC-MS/MS. Unstimulated controls were obtained by simultaneous injection of sterile PBS into the opposite paw of each mouse. Data are expressed as mean ± SEM in pg, n = 4 mice/group. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. the corresponding USA300 wild-type strain using one-way ANOVA with Tukey multiple comparison post hoc test